HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Combination of intravenous immunoglobulins and lenalidomide in the treatment of scleromyxedema.

AuthorsFlorence Brunet-Possenti, Olivier Hermine, Eduardo Marinho, Béatrice Crickx, Vincent Descamps
JournalJournal of the American Academy of Dermatology (J Am Acad Dermatol) Vol. 69 Issue 2 Pg. 319-20 (Aug 2013) ISSN: 1097-6787 [Electronic] United States
PMID23866873 (Publication Type: Case Reports, Letter)
Chemical References
  • Immunoglobulins, Intravenous
  • Thalidomide
  • Lenalidomide
Topics
  • Administration, Oral
  • Adult
  • Biopsy, Needle
  • Disease Progression
  • Dose-Response Relationship, Drug
  • Drug Administration Schedule
  • Drug Therapy, Combination
  • Follow-Up Studies
  • Humans
  • Immunoglobulins, Intravenous (therapeutic use)
  • Immunohistochemistry
  • Lenalidomide
  • Male
  • Scleromyxedema (diagnosis, drug therapy)
  • Severity of Illness Index
  • Thalidomide (analogs & derivatives, therapeutic use)
  • Treatment Outcome

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: